TTs include BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) which inhibit the commonly over‐activated mitogen‐activated protein kinase (MAPK) pathway, responsible for cell proliferation and survival in melanoma.2 The gene discussed is BRAF; the disease is melanoma.